CompletedNot Applicable

CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

China1,029 participantsStarted 2021-08-20

Plain-language summary

In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete revascularization and perform whole-exome sequencing for enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored, irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor prognosis of ACS.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1\. In-patients with acute coronary syndrome to undergo PCI 2. Complete revascularization during the index hospitalization 3. Written informed consent Exclusion Criteria: * 1\. Periprocedural complications (coronary artery dissection, perforation, myocardial infarction, stroke, death) 2. Planned coronary revascularization at discharge 3. Patients with severe chronic disease (uremia, liver cirrhosis, COPD (chronic obstructive pulmonary disease) 4. Abnormal blood counts caused by hematological diseases 5. Diagnosed malignancy

What they're measuring

prevalence of CHIP mutations

Timeframe: 24 hours

Trial details

NCT IDNCT04987268

SponsorShenyang Northern Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-08-20

View on ClinicalTrials.gov More ACS trials